Fagron SlimCarb® assists in the treatment of obesity by inhibiting salivary, pancreatic and intestinal a-glycosidase enzyme activity, thereby promoting a delayed absorption of
carbohydrates and glucose. In addition, SlimCarb® has an inhibitory action on pancreatic lipase – an enzyme responsible for digesting fat.

Reduces carbohydrate, glucose and fat absorption SlimCarb® blocks the activity of salvatory & intestinal enzymes, thereby inhibiting the absorption of carbohydrates and glucose. This anti-nutrient effect of the phytoactive on a-amylase and a-glycosidase assists in the management of obesity. SlimCarb® similarly inhibits pancreatic
lipase, an enzyme responsible for breaking down 50 – 70% of the total fats we ingest. The result is a direct prevention of weight gain.